Synairgen PLC's (LON:SNG) Richard Marsden tells Proactive London's Andrew Scott they've received approval to launch a phase II clinical trial of its lead drug in patients with COVID-19.
SNG001 is an inhaled formulation of interferon-beta-1a and is currently being developed to treat people with chronic obstructive pulmonary disease (COPD) that also have respiratory viral infections.